Insulin degludec plus liraglutide
Indication
Treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control, in combination with oral glucose-lowering medicinal products when these alone, or combined with basal insulin, do not provide adequate glycaemic control
Black
Brand:
Xultophy®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
The combination product insulin degludec plus liraglutide (Xultophy®▼) is not recommended to treat type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone, or combined with basal insulin, do not adequately provide glycaemic control.
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria
Supporting documents: